Physician profile
Patrick Bentley
NPI 1386613719
$2,595.50
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.12 · 2020: $55.31 · 2021: $315 · 2022: $906 · 2023: $771 · 2024: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $422.63 | 2020-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $380.30 | 2022-2024 | Invega Sustenna, Invega Trinza, Spravato |
| Abbvie INC. | $333.25 | 2021-2024 | Vraylar |
| Axsome Therapeutics, INC. | $305.56 | 2022-2024 | Auvelity, Sunosi |
| Alkermes, INC. | $293.20 | 2021-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $223.70 | 2021-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $188.70 | 2022-2024 | Uzedy, Austedo Xr |
| Indivior INC. | $170.44 | 2022-2024 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $76.28 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $65.70 | 2022-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Allergan, INC. | $45.11 | 2019-2020 | |
| Lundbeck LLC | $35.04 | 2022 | |
| Noven Therapeutics, LLC | $26.22 | 2021-2023 | Secuado |
| Corium, LLC | $15.35 | 2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $14.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Bentley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.